Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

Mirabegron (MBR) is a β<sub>3</sub>-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (<i>F</i>), the development of novel MBR formulations has garnered increasing attention. Recently, co-amorphous dispersio...

Full description

Bibliographic Details
Main Authors: Seo-Yeon Kim, Byung Hoon You, Mingoo Bae, Seung Yon Han, Kiwon Jung, Young Hee Choi
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Pharmaceutics
Subjects:
mirabegron
co-amorphous dispersion
pharmacokinetics
bioavailability
tissue distribution
Online Access:https://www.mdpi.com/1999-4923/15/9/2277

Internet

https://www.mdpi.com/1999-4923/15/9/2277

Similar Items